Stephen Juvet, GI Snell, Saskia Bos, Marie M Budev, John R Greenland, Kieran Halloran, Sandra Lindstedt, Laurie D Snyder, Rayid Abdulqawi, Atefeh Abedini, Selim M Arcasoy, Meghan Aversa, Alberto Benazzo, Daniel R Calabrese, Fiorella Calabrese, Marlene Cano, Kevin Chan, Satish Chandrashekaran, D. Darley, Amir Emtiazjoo, Tara Fallah, Laurent Godinas, René Hage, Don Hayes, Howard J. Huang, Jana Kleinerová, Sakhee Kotecha, Akshay Kumar, Francesca Lunardi, Jorge Mallea, Tereza Martinu, Federica Meloni, Anoop Mohandas, Eric D. Morrell, A Nair, Rene Novysedlak, Michael Perch, Federica Pezzuto, C Picard, Peter Riddell, Anja C. Roden, Justin P Rosenheck, Julie Semenchuk, Unmil Shah, Heather Strah, Laneshia K Tague, Rade Tomic, Anil J Trindade, Katherine Vandervest, Geert M. Verleden, G Westall, Ciara M. Shaver
Lung transplantation (LTx) is an accepted therapy for select patients with end-stage lung disease. Since the first successful human lung transplant over 60 years ago, the field has evolved significantly, with advancements in donor selection and preservation technologies, surgical techniques, and antimicrobial prophylaxis. Despite these improvements, acute lung allograft failure and chronic lung allograft dysfunction (CLAD) continue to pose challenges to long-term patient survival.1 Survival rates post-LTx remain low compared to other solid organ transplants, with a median survival of 6.7 years with only modest improvements observed over the past 30 years.